Envudeucitinib Could Be a Real Disruptor — A Tactical Long on ALMS Ahead of Commercial Readouts
Alumis' oral TYK2 candidate envudeucitinib just cleared a major Phase 3 hurdle and the company has bolstered its balance sheet with a $300M upsized offering. At a $3.0B market cap and stretched valuation metrics, the stock is priced for perfection, but the combination of clinical success, improved funding and a meaningful short base creates a tacti…